Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility.
暂无分享,去创建一个
[1] M. Resnick,et al. Two-dimensional analysis of proteins in unprocessed human urine using double stain. , 1993, The Journal of urology.
[2] O. Vesterberg,et al. Unconcentrated human urinary proteins analysed by high resolution two‐dimensional electrophoresis with narrow pH gradients: Preliminary findings after occupational exposure to cadmium , 1985 .
[3] J. J. Edwards,et al. Proteins of human urine. II. Identification by two-dimensional electrophoresis of a new candidate marker for prostatic cancer. , 1982, Clinical chemistry.
[4] M. Schrader,et al. Human beta-defensin-1: A urinary peptide present in variant molecular forms and its putative functional implication. , 1998, European journal of medical research.
[5] O John Semmes,et al. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] A. Belldegrun,et al. The changing natural history of renal cell carcinoma. , 2001, The Journal of urology.
[7] M S Pepe,et al. Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.
[8] G. Wright,et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. , 2001, The American journal of pathology.
[9] Geoffrey E. Hinton,et al. Learning internal representations by error propagation , 1986 .
[10] J. Glaspy. Therapeutic options in the management of renal cell carcinoma. , 2002, Seminars in oncology.
[11] Michael B Cohen,et al. Biomarkers for the Detection of Bladder Cancer , 2001, Advances in anatomic pathology.
[12] M. Hammond,et al. Issues and barriers to development of clinically useful tumor markers: a development pathway proposal. , 2002, Seminars in oncology.
[13] E. Petricoin,et al. Serum proteomic patterns for detection of prostate cancer. , 2002, Journal of the National Cancer Institute.
[14] S. Huang,et al. Urinary NMP22 and renal cell carcinoma. , 2000, Urology.
[15] D. Dunger,et al. Freezing method affects the concentration and variability of urine proteins and the interpretation of data on microalbuminuria , 2000, Diabetic medicine : a journal of the British Diabetic Association.
[16] M. Dowsett,et al. Biological markers: maintaining standards , 2000, British Journal of Cancer.
[17] P. Schellhammer,et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.
[18] B. Konety,et al. Urine based markers of urological malignancy. , 2002, The Journal of urology.
[19] D. Chan,et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. , 2002, Clinical chemistry.
[20] Uwe Claussen,et al. Mass spectrometry meets chip technology: A new proteomic tool in cancer research? , 2001, Electrophoresis.
[21] D. Vonderschmitt,et al. Electrophoretic, chromatographic and immunological studies of human urinary proteins , 1995, Electrophoresis.
[22] J. J. Edwards,et al. Proteins of human urine. III. Identification and two-dimensional electrophoretic map positions of some major urinary proteins. , 1982, Clinical chemistry.
[23] N. Anderson,et al. Proteins of human urine. I. Concentration and analysis by two-dimensional electrophoresis. , 1979, Clinical chemistry.
[24] R. Wahl,et al. Towards defining the urinary proteome using liquid chromatography‐tandem mass spectrometry I.Profiling an unfractionated tryptic digest , 2001, Proteomics.
[25] D. L. Diamond,et al. Detection of β-defensins secreted by human oral epithelial cells , 2001 .
[26] M. Goligorsky,et al. Toward proteomics in uroscopy: urinary protein profiles after radiocontrast medium administration. , 2001, Journal of the American Society of Nephrology : JASN.
[27] R. Bast,et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.
[28] B. Koçak,et al. Value of urinary NMP-22 in patients with renal cell carcinoma. , 2002, Urology.
[29] E. Petricoin,et al. Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip , 2000 .
[30] G. Wright,et al. Proteinchip® surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures , 1999, Prostate Cancer and Prostatic Diseases.
[31] S. Weinberger,et al. Recent advancements in surface‐enhanced laser desorption/ionization‐time of flight‐mass spectrometry , 2000, Electrophoresis.
[32] D. Sargent,et al. Issues in clinical trial design for tumor marker studies. , 2002, Seminars in oncology.
[33] S M Hanash,et al. Proteomic Approaches within the NCI Early Detection Research Network for the Discovery and Identification of Cancer Biomarkers , 2001, Annals of the New York Academy of Sciences.
[34] Peter Albers,et al. Analysis of microdissected prostate tissue with ProteinChip arrays--a way to new insights into carcinogenesis and to diagnostic tools. , 2002, International journal of molecular medicine.
[35] Christina H. Park,et al. Human beta-defensin-1: an antimicrobial peptide of urogenital tissues. , 1998, The Journal of clinical investigation.
[36] W. Sadler,et al. The Effect of Storage Ph on the Precipitation of Proteins in Deep Frozen Urine Samples , 1987, Annals of clinical biochemistry.
[37] P. Schellhammer,et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. , 2002, Clinical chemistry.
[38] M. Nakazato,et al. Structural analysis of human beta-defensin-1 and its significance in urinary tract infection. , 2000, Nephron.
[39] M. Rubin,et al. Molecular markers for renal cell carcinoma: impact on diagnosis and treatment. , 2001, Seminars in urologic oncology.
[40] B. Kramer,et al. Trends in biomarker research for cancer detection. , 2001, The Lancet. Oncology.
[41] J. X. Pang,et al. Biomarker discovery in urine by proteomics. , 2002, Journal of proteome research.
[42] F. Marshall,et al. Beta Defensin-1, Parvalbumin, and Vimentin: A Panel of Diagnostic Immunohistochemical Markers for Renal Tumors Derived From Gene Expression Profiling Studies Using cDNA Microarrays , 2003, The American journal of surgical pathology.
[43] Y. Lee,et al. Urinary proteins with pro-apoptotic and antitumor activity , 2000, Apoptosis.
[44] J. Celis,et al. Towards a comprehensive database of proteins from the urine of patients with bladder cancer. , 1996, The Journal of urology.
[45] K. Lillemoe,et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. , 2002, Cancer research.
[46] P. Schellhammer,et al. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. , 2001, Cancer research.
[47] J. Celis,et al. Psoriasin (S100A7): A putative urinary marker for the follow‐up of patients with bladder squamous cell carcinomas , 1999, Electrophoresis.
[48] M. Nakazato,et al. Structural Analysis of Human β-Defensin-1 and Its Significance in Urinary Tract Infection , 2000, Nephron.
[49] U. Stenman. Tumor-associated trypsin inhibitor. , 2002, Clinical chemistry.
[50] A. Rodríguez-Cuartero,et al. Urinary beta-glucuronidase in renal cell carcinoma. , 2000, Clinical nephrology.
[51] James L. McClelland,et al. Parallel distributed processing: explorations in the microstructure of cognition, vol. 1: foundations , 1986 .